Our Milestones and Achievements

Celebrating more than 23 years of quality cord blood banking and more...

We are focused on helping people live healthier, happier, and longer by providing reliable healthcare solutions through innovation, technological advancement, and commitment to quality. Here are some of the initiatives we have made during the year.

2024

  • Stemlife Malaysia attained AABB accreditation for the fourth time, and successfully completed MS ISO 15189:2022 assessment and reaccreditation for its medical testing laboratory.
  • Cordlife Hong Kong attained AABB accreditation for the seventh time.
  • Healthbaby Hong Kong attained CAP accreditation for the seventh time.
  • Cordlife Philippines celebrated its 15th Anniversary and secured a license from the Department of Health to operate their clinical diagnostics laboratory.

2023

  • Cordlife Group expanded global footprint to Cambodia, offering various screening services including carrier screening and genetic talent testing. The Group has also incorporated a wholly-owned subsidiary in Vietnam to provide, amongst others, management consulting and development services.
  • Stemlife Malaysia entered into an agreement with Loh Guan Lye Specialists Centre to offer peripheral blood stem cell (“PBSC”) banking services. Stemlife Malaysia also appointed Medixcell for cGMP-certified umbilical cord MSC manufacturing in Malaysia. They subsequently launched MSC expansion service in Malaysia, offering MSC storage option to meet the future demand for advanced cell therapies and regenerative medicine.
  • Healthbaby Hong Kong launched placenta storage, using exclusive CellMaxima™ technology to preserve placental stem cells.
  • Cordlife Hong Kong collaborated with Hong Kong Regen Medtech Limited for a two-year study on the application of umbilical cord MSC-derived secretomes for osteoarthritis treatment. Cordlife Hong Kong launched an expanded panel of lifestyle genetic tests covering sports, skin, diet and health, as well as in-house Allergy DNA and Pharmacogenomics tests.
  • Cordlife Philippines opened its Davao City satellite office in collaboration with the Lanang Premiere Doctors Hospital. Cordlife Philippines attained AABB accreditation for the fourth time, and passed ISO 9001:2015 audit for the fifth time.
  • Stemlife Malaysia and Cordlife Philippines launched Chromosomal Microarray Analysis, offering a higher-resolution genome analysis than traditional prenatal screening tests for detecting chromosomal abnormalities.
  • Cordlife Indonesia passed the ISO 9001:2015 surveillance audit and attained AABB accreditation for the third time. Cordlife Indonesia launched a brand-new medical laboratory for clinical pathology in Central Jakarta providing high-quality, convenient and cost-effective services.
  • Cordlife India renewed its DCGI licence, attained AABB accreditation for the sixth time; NABL accreditation for the second time; WHO GMP certification for the tenth time, and passed the ISO 9001:2015 audit for the third time. Cordlife India opened a diagnostics laboratory in Kolkata, offering value-added services and various health screening packages.

2022

  • Cordlife launched corporate social responsibility campaign to commemorate its 21st Anniversary.
  • Cordlife Singapore partnered AMILI Pte. Ltd. to launch the first-ever gut microbiome banking service in Southeast Asia.
  • Cordlife Indonesia launched Bebegene®, the country’s first newborn genetic screening service.
  • Stemlife Malaysia and Cordlife Hong Kong received re-accreditation from AABB.
  • Cordlife Singapore expands suite of paediatric services with Earscreen™ and Talent Screening services.
  • Cordlife Indonesia partnered Dharmais Cancer Hospital in providing stem cell cryopreservation services to leukaemia patients in support of cellular therapy.

2021

  • Cordlife embarked on a digital transformation journey to change how the Group goes digital to better impact, externally for clients and internally for employees.
  • Cordlife Singapore and Cordlife Hong Kong launched OptiQ, a first-of-its-kind corneal lenticule banking service.
  • Cordlife Singapore partnered with SingHealth Duke-NUS Academic Medical Centre to advance stem cell technology to a first in-man clinical trial in Singapore. In addition, Cordlife Singapore also launched Moms Up, a one-stop solution app that provides localised advice on conceiving, pregnancy, and postpartum support for women in Singapore.
  • Stemlife Malaysia received The BrandLaureate World’s e-Branding Award – Best Brand of the Year 2020 in Innovation Stem Cell Solutions, from The World Brands Foundation. Stemlife Malaysia also launched Bebegene, a newborn genetic screening service.
  • Cordlife Hong Kong launched Cordlife Carrier Screening, Cordlife Hereditary Cancer Screening, Cordlife Hereditary Cardiac Disease Screening and Cordlife Hereditary Neurological Disease Screening.
  • Cordlife Hong Kong and Cordlife Indonesia launched MIRA, a miRNA-based receptivity analysis testing to help couples undergoing IVF in determining the best time for embryo transfer to increase their chance of pregnancy.
  • Cordlife Hong Kong, Cordlife Indonesia and Cordlife Philippines launched Cordlife Alliance, a community banking programme that allows Cordlife’s clients to help another Cordlife family in need of a cord blood unit.
  • Cordlife India launched in-house diagnostic services.
  • Cordlife India attained NABL accreditation for the first time

2020

  • Cordlife Indonesia launched PreImplantation Genetic Screening to help improve the likelihood of a successful pregnancy of couples undergoing in vitro fertilisation (“IVF”) treatment. They subsequently launched Genelife, a lifestyle genetic testing and Umbilical Cord Wharton’s Jelly banking service.
  • Cordlife Hong Kong and Healthbaby Hong Kong launched paediatric allergy testing to detect up to 104 allergens; bebegene®, a newborn genetic screening with comprehensive assessment of more than 120 genetic related diseases in infants and children aged 0-3; and LifeScreen, a talent genetic test panel for children.
  • Cordlife Philippines celebrated the inauguration of new Cordlife satellite offices in St. Luke’s Medical Center Quezon City, Cebu City, and Davao City
  • Stemlife Malaysia launched non-invasive prenatal testing in Malaysia.

2019

  • Healthbaby Hong Kong’s facility became the first and only private cord blood bank in the country to receive FACT accreditation.
  • Officially opened the largest full-fledged cord blood and tissue banking facility in Indonesia.
  • Appointed marketing agent in Bangladesh, one of the fastest growing economies of the world.
  • Cordlife Philippines received re-accreditation from AABB and remains the only AABB accredited facility in the country.
  • Cordlife Indonesia’s facility became the first and only in Indonesia to receive AABB accreditation.

2018

  • Awarded "Best Family Cord Blood Bank Award" by Mummys Market.
  • More than 60,000 parents stored their child’s precious stem cells with Cordlife.

2017

  • First cord blood bank in the Philippines to be AABB-accredited.
  • More than 56,000 parents stored their child's precious stem cells with Cordlife.
  • Launched NICE®, a clinically approved non-invasive prenatal test in Indonesia and Philippines.
  • Launched Cordlife’s first-ever public "Cordlife Donation Drive" in Singapore and raised both cash and donations-in-kind for Singapore Children’s Society.

2016

  • First Singapore-based cord blood bank to launch in Myanmar and Vietnam.
  • Received Accreditation from College of American Pathologists for its Hong Kong and India Subsidiaries.
  • Launched Cordlife’s inaugural "Cordlife Donation Drive" in Singapore and raised donations-in-kind for Children’s Aid Society – Melrose Home.

2015

  • Received accreditation from FACT which ensures the global standard of excellence in patient care and laboratory practices.
  • Cordlife is one out of the six private cord blood banks worldwide that is double-accredited and the first in Southeast Asia to achieve the dual-accreditation status with AABB and FACT (The Foundation for the Accreditation of Cellular Therapy).
  • Launched the Cordlife-Jalan Kayu Pre-School Headstart Fund with a sponsorship of $150K to give young children from low-income families a chance in pre-school education.
  • Partnered with autism and epilepsy treatment pioneer, Dr Michael Chez from Sutter Medical Group and Sutter Neuroscience Institute in the continued study of autologous cord blood cells treatments.
  • Received the 16th SIAS Investors Choice Award (Runnerup), Singapore Corporate Governance Award (SCGA) 2015, Mid and Small Category
  • Honoured by Forbes Asia as one of the "Best Under a Billion" companies in November 2015.
  • Acquired the first and largest cord blood bank in Malaysia, Stemlife Berhad as one of its subsidiaries.

2014

  • More than 45,000 parents stored their child’s precious stem cells with Cordlife.
  • Collaborated with Make-A-Wish Foundation® (Singapore) Ltd granting the wishes of children with life-threatening medical conditions to enrich the human experience with hope, strength and joy.
  • Enhanced Cordlife Pledge:360° assures quality processing and storage standards.

2013

  • Cordlife Group Limited moved to its fully owned, 23,000sqft office and laboratory facility in A'Posh Bizhub, Yishun. The facility is capable of storing up to 650,000 cord blood units.
  • First private cord blood bank in Singapore to launch automated processing system to facilitate the optimisation of cord blood stem cells for maximum transplant success*.
  • Re-accredited by American Association of Blood Banks (AABB).
  • Launched provision of umbilical cord lining banking services in Singapore with patented technology, CellOptima™ that is exclusively available at Cordlife capable of isolating EpSCs and MSCs, two types of stem cells present in the umbilical cord.
  • Awarded 'Most Transparent Company Award' by SIAS Inestors Choice

2012

  • Successfully listed on Singapore Exchange Main Board on 29 March 2012.
  • More than 40,000 clients stored their precious stem cells with Cordlife.

2011

  • CordLife Pte Ltd renamed to "Cordlife Group Limited".
  • Launched Cordlife Care360° Safeguard programme.
  • Re-accredited by American Association of Blood Banks (AABB).
  • Launched provision of umbilical cord tissue banking services in Hong Kong.
  • Hong Kong facility accredited by American Association of Blood Banks (AABB)

2010

  • First-ever release of autologous cord blood for Neuroblastoma.
  • Released autologous cord blood for Cerebral Palsy.
  • More than 25,000 parents stored their child’s precious stem cells with Cordlife.
  • Celebrated 10 years of quality cord blood banking.

2009

  • Re-accredited by American Association of Blood Banks (AABB).
  • First-ever release of autologous cord blood for Cerebral Palsy
  • Launched Cordlife Quality Guarantee, a warranty to protect Cordlife clients.
  • Launched Cordlife Circle, a members-only benefit programme.
  • Launched Preferential Plan upgrades for clients.

2008

  • Re-accredited by American Association of Blood Banks (AABB).
  • Launch of automated processing system to maximise recovery of cells for transplant use.

2007

  • Expanded to new Science Park II facility.
  • Cordlife Hong Kong achieved ISO:9001.

2005

  • Received accreditation from American Association of Blood Banks (AABB)
  • AABB's Accreditation Program strives to improve the quality and safety of collecting, processing, testing, distributing and administering blood and blood products by assessing the quality and operational systems in place within the facility.
  • Offered Medicord, a stem cell transplant insurance programme.
  • Entered Hong Kong and People's Republic of China (PRC) markets.

2002

  • First cord blood released for sibling-use.
  • Laboratory at Camden Medical Centre opened for public viewing.

2001

  • CordLife Pte Ltd established and licensed by Ministry of Health (MOH) Singapore